Yulia Skovpen

Yulia Skovpen

Auto-generated profile, based on publicly available information

Yulia Skovpen

Rancho BioSciences, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
VSVishal B Siramshetty
Vishal B Siramshetty
IGIvan Grishagin
Ivan Grishagin
ÐNÐắc-Trung Nguyễn
Ðắc-Trung Nguyễn
TPTyler Peryea
Tyler Peryea
YSYulia Skovpen
Yulia Skovpen
NSNoel T Southall
Noel T Southall
The United States has a complex regulatory scheme for marketing drugs. Understanding drug regulatory status is a daunting task that requires integrating data from many sources from the United States Food and Drug Administration (FDA), US government publications, and other processes related to drug development. At NCATS, we created Inxight Drugs (https://drugs.ncats.io), a web resource that attempts to address this challenge in a systematic manner. NCATS Inxight Drugs incorporates and unifies a wealth of data, including those supplied by the FDA and from independent public sources. The database offers a substantial amount of manually curated literature data unavailable from other sources. Currently, the database contains 125 036 product ingredients, including 2566 US approved drugs, 6242 marketed drugs, and 9684 investigational drugs. All substances are rigorously defined according to the ISO 11238 standard to comply with existing regulatory standards for unique drug substance identification. A special emphasis was placed on capturing manually curated and referenced data on treatment modalities and semantic relationships between substances. A supplementary resource ‘Novel FDA Drug Approvals’ features regulatory details of newly approved FDA drugs. The database is regularly updated using NCATS Stitcher data integration tool that automates data aggregation and supports full data access through a RESTful API.

21 March 2018 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
IKI. I. Krasnuk
I. I. Krasnuk
ТКТатьяна Михайловна Кошелева
Татьяна Михайловна Кошелева
ABA. V. Belyatskaya
A. V. Belyatskaya
ОСОльга Ивановна Степанова
Ольга Ивановна Степанова
YSYu. Skovpen'
Yu. Skovpen'
ЛОЛюбовь Витальевна Овсянникова
Любовь Витальевна Овсянникова
Indomethacin, a non-steroid anti-inflammatory drug (NSAID), has been used in different spheres of medicine since the 1960s. It is successfully administered as an anti-inflammatory and pain-relieving medication in rheumatoid and other diseases. According to recent research, indomethacin may become a promising drug enhancing endogenous remyelination in patients with multiple sclerosis. Also, indomethacin affects cell proliferation and invasion, thus it is used to manage pancreatic cancer in patients with hyperglycemia. In addition, indomethacin can inhibit protein synthesis in colorectal carcinoma and other types of cancer cells. The article reviews modern indomethacin medications and the different dosage forms on the Russian pharmaceutical market. Indomethacin poor water solubility is one of the reasons for decreasing its biopharmaceutical characteristics. According to the conducted research, a prospective way to improve indomethacin solubility and bioavailability is the Solid Dispersion (SD) method. SDs are bi- or multicomponent systems consisting of the drug and the carrier. They are a highly dispersed solid phase of the drug or molecular-dispersed solid solutions with a partial formation of a variable composition complex and a carrier. The article provides a brief overview on different aspects of obtaining, investigating, and applying indomethacin SDs with various polymers.